| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S0305-7372(96)90002-X |
| P698 | PubMed publication ID | 8841390 |
| P2093 | author name string | Joel S | |
| P2860 | cites work | The treatment of metastatic germ-cell testicular tumours with bleomycin, etoposide and cis-platin (BEP) | Q24564931 |
| Structure and mechanism of DNA topoisomerase II | Q27732221 | ||
| The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene | Q28201279 | ||
| Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma | Q28297805 | ||
| Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours | Q28323966 | ||
| FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer | Q33363249 | ||
| Etoposide in patients with previously untreated non-small-cell lung cancer: a phase I study | Q33370183 | ||
| Chronic daily administration of oral etoposide in refractory lymphoma | Q33394746 | ||
| Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial | Q33395941 | ||
| High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer | Q33445594 | ||
| Phase II study of prolonged oral etoposide in combination with intravenous cisplatin in advanced non-small cell lung cancer | Q33488666 | ||
| Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. | Q33490795 | ||
| Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer | Q33490956 | ||
| Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. | Q33491457 | ||
| Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer. | Q33492120 | ||
| Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer | Q33492550 | ||
| Etoposide, leucovorin, 5-fluorouracil (ELF) combination chemotherapy for advanced gastric cancer: experience with two treatment schedules incorporating intravenous or oral etoposide | Q33492625 | ||
| Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer | Q33492816 | ||
| Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial | Q33493331 | ||
| Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study | Q33493589 | ||
| Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance | Q34161314 | ||
| Topoisomerase II: its functions and phosphorylation | Q35235997 | ||
| Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia | Q35368659 | ||
| Local base sequence preferences for DNA cleavage by mammalian topoisomerase II in the presence of amsacrine or teniposide. | Q35790599 | ||
| Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease | Q35978022 | ||
| A consensus sequence for cleavage by vertebrate DNA topoisomerase II. | Q36010020 | ||
| Continuous-infusion verapamil with etoposide in relapsed or resistant paediatric cancers | Q36080770 | ||
| A phase II study of oral etoposide in elderly patients with small cell lung cancer | Q36204361 | ||
| Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group | Q36678707 | ||
| Current status of etoposide in the management of small cell lung cancer | Q37155323 | ||
| Etoposide in the management of non-small cell lung cancer | Q37155339 | ||
| Etoposide. Current and future status | Q37619406 | ||
| The evolving role of etoposide in the management of lymphomas and Hodgkin's disease | Q37619429 | ||
| Etoposide in acute leukemia. Past experience and future perspectives | Q37619447 | ||
| The biochemistry of P-glycoprotein-mediated multidrug resistance | Q38364215 | ||
| Mechanism of action of antitumor drug etoposide: a review | Q39290578 | ||
| The clinical pharmacology of etoposide and teniposide | Q39658304 | ||
| Incidence, previous treatment and chromosome characteristics of secondary acute non-lymphocytic leukemia | Q39827097 | ||
| Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside) | Q40089603 | ||
| Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial | Q71671974 | ||
| Secondary tumours following etoposide containing therapy for germ cell cancer | Q71687293 | ||
| Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study | Q71832952 | ||
| Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors* | Q71939857 | ||
| Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B | Q71961886 | ||
| Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer | Q71989508 | ||
| A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity | Q72038139 | ||
| Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated With Etoposide-Containing Chemotherapy | Q72066717 | ||
| Clinical and pharmacokinetic overview of parenteral etoposide phosphate | Q72149468 | ||
| A phase I trial of high-dose oral tamoxifen and CHOPE | Q72163473 | ||
| High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients | Q72311506 | ||
| Chronic oral etoposide in advanced breast cancer | Q72314335 | ||
| Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer | Q72323491 | ||
| Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide | Q72354134 | ||
| Phase I clinical and pharmacokinetic study of oral etoposide phosphate | Q72354138 | ||
| Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosis | Q72422052 | ||
| Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results | Q72559645 | ||
| The treatment of older adult patients with acute myeloid leukemia by triple infusion chemotherapy | Q72655098 | ||
| High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator | Q72667226 | ||
| Oral etoposide is active against platinum-resistant epithelial ovarian cancer | Q72681506 | ||
| Phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with advanced non-small-cell lung cancer | Q72681515 | ||
| Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin | Q72793441 | ||
| Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer | Q72843397 | ||
| Low-dose oral etoposide in epithelial cancer of the ovary | Q72884098 | ||
| Myelodysplastic syndrome and acute myeloid leukemia after treatment for solid tumors of childhood | Q72938893 | ||
| Phase II trial of VP-16-213 in advanced ovarian carcinoma | Q93632425 | ||
| EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma | Q54235356 | ||
| Thymocyte apoptosis induced by p53-dependent and independent pathways. | Q54242475 | ||
| Determinants of Response to the DNA Topoisomerase II Inhibitors Doxorubicin and Etoposide in Human Lung Cancer Cell Lines | Q54277224 | ||
| Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer | Q54294219 | ||
| Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. | Q54388390 | ||
| Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. | Q54401416 | ||
| Phase II randomized study of cisplatin plus etoposide phosphate or etoposide in the treatment of small-cell lung cancer | Q61889960 | ||
| Epipodophylin derivative (VP 16-23) in malignant teratomas and choriocarcinomas | Q66695660 | ||
| Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group | Q67485745 | ||
| Chronic oral etoposide in non-small cell lung carcinoma | Q67503634 | ||
| Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer | Q67557072 | ||
| Relation of systemic exposure to unbound etoposide and hematologic toxicity | Q68004991 | ||
| A randomized trial of five cisplatin-containing treatments in patients with metastatic non-small-cell lung cancer: a Southwest Oncology Group study | Q68239298 | ||
| Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study | Q68249940 | ||
| Phase II trial of daily oral etoposide in patients with advanced non-small cell lung cancer | Q68272896 | ||
| Chromosome aberrations induced by etoposide (VP-16) are not random | Q68584383 | ||
| Changes in the clearance of total and unbound etoposide in patients with liver dysfunction | Q68588419 | ||
| Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide | Q68992349 | ||
| Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol | Q69054631 | ||
| Pharmacokinetics of high dose etoposide (VP 16-213) | Q69316432 | ||
| Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial | Q69335172 | ||
| A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer | Q69355056 | ||
| Phase II study with etoposide in previously untreated advanced breast cancer | Q69664204 | ||
| Increase in etoposide-induced topoisomerase II-mediated DNA breaks after cell synchronization induced by low doses of methotrexate | Q69828792 | ||
| VP-16-213 in the treatment of stage III and IV diffuse large cell lymphoma | Q69899414 | ||
| Altered protein binding of etoposide in patients with cancer | Q69936282 | ||
| The chemotherapeutic drug melphalan induces breakage of chromosomes regions rearranged in secondary leukemia | Q69947855 | ||
| Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay | Q70058382 | ||
| Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer | Q70078067 | ||
| Variable bioavailability following repeated oral doses of etoposide | Q70118152 | ||
| Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research | Q70222899 | ||
| Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease | Q70434944 | ||
| Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation | Q70457573 | ||
| Secondary neoplasms following treatment of malignant germ cell tumors | Q70470652 | ||
| Prolonged oral etoposide in small cell lung cancer | Q70472935 | ||
| Chronic oral etoposide in small-cell lung cancer: clinical and pharmacokinetic results | Q70472939 | ||
| Synergistic interactions of etoposide and interleukin-1 alpha are not due to DNA damage in human melanoma cells | Q70534718 | ||
| Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide | Q70543495 | ||
| Bioavailability of low-dose oral etoposide | Q70543559 | ||
| Report of the Cancer Therapy Evaluation Program monitoring plan for secondary acute myeloid leukemia following treatment with epipodophyllotoxins | Q70616408 | ||
| Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide | Q70657148 | ||
| Predicting etoposide toxicity: relationship to organ function and protein binding | Q70891308 | ||
| Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer | Q71132157 | ||
| Stability of the i.v. and oral formulations of etoposide in solution | Q71581692 | ||
| Chemotherapy of small cell carcinoma of the lung with V. P. 16–213 | Q40144836 | ||
| VP16-213 (etoposide). A critical review of its activity | Q40331933 | ||
| Etoposide: twenty years later. | Q40449883 | ||
| Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism | Q40476934 | ||
| Secondary Leukemia Associated With a Conventional Dose of Etoposide: Review of Serial Germ Cell Tumor Protocols | Q40484262 | ||
| Topoisomerase II enzymes and mutagenicity | Q40590105 | ||
| Clinical reversal of the multidrug resistance phenotype: true tumour modulation or pharmacokinetic interaction? | Q40594137 | ||
| Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors | Q40630446 | ||
| Chromatin structure, not DNA sequence specificity, is the primary determinant of topoisomerase II sites of action in vivo | Q40641040 | ||
| Ifosfamide and etoposide in recurrent childhood acute lymphoblastic leukemia. | Q40689172 | ||
| Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells | Q40694343 | ||
| Topoisomerase expression in cancer cell lines and clinical samples | Q40694357 | ||
| Schedule-dependent topoisomerase II-inhibiting drugs | Q40694380 | ||
| Treatment of gastric adenocarcinoma with the combination of etoposide, adriamycin and cisplatin (EAP): comparison between two schedules | Q40706434 | ||
| Chronic daily administration of oral etoposide--a phase I trial | Q40777022 | ||
| When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplastic drugs | Q40806917 | ||
| DNA topoisomerase I and II in cancer chemotherapy: update and perspectives | Q40853538 | ||
| Chronic administration of etoposide in the treatment of non-Hodgkin's lymphoma | Q40901652 | ||
| Multidrug resistance in cancer chemotherapy | Q41052675 | ||
| Pharmacodynamics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer | Q41077289 | ||
| Potentiation of TNF-mediated cell killing by VP-16: relationship to DNA single-strand break formation | Q41212501 | ||
| In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy | Q41337000 | ||
| Etoposide-induced cell cycle delay and arrest-dependent modulation of DNA topoisomerase II in small-cell lung cancer cells. | Q41431305 | ||
| In vitro and in vivo effects of cisplatin and etoposide in combination on small cell lung cancer cell lines | Q41437465 | ||
| Expression of the multidrug resistance-associated protein (MRP) gene in human lung tumours and normal tissue as determined by in situ hybridisation | Q41504161 | ||
| Potentiation of etoposide cytotoxicity against a human ovarian cancer cell line by pretreatment with non-toxic concentrations of methotrexate or aphidicolin | Q41651104 | ||
| Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pretreated with low doses of methotrexate | Q41747802 | ||
| Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline | Q41752574 | ||
| Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity | Q41774519 | ||
| Etoposide kinetics in patients with obstructive jaundice | Q42050531 | ||
| Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia | Q42150861 | ||
| A prospective randomised study in limited disease small cell carcinoma--doxorubicin and vincristine plus either cyclophosphamide or etoposide | Q42274608 | ||
| A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. | Q42275184 | ||
| Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy | Q42277372 | ||
| P glycoprotein (P-gp) and drug resistance--time for reappraisal? | Q42390230 | ||
| Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II. | Q42810685 | ||
| Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada | Q43614841 | ||
| Clinical pharmacodynamics of continuous-infusion etoposide | Q43858846 | ||
| Prospective study of etoposide scheduling in combination chemotherapy for limited disease small cell lung carcinoma | Q43899570 | ||
| Prognostic factors for favorable outcome in disseminated germ cell tumors | Q43907839 | ||
| Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial | Q43972876 | ||
| Etoposide versus etoposide plus high-dose cisplatin in the management of advanced non-small cell lung cancer. Results of a prospective randomized FONICAP trial. Italian Lung Cancer Task Force | Q44046900 | ||
| Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies | Q44246178 | ||
| Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia | Q44461372 | ||
| Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group | Q45039641 | ||
| Small deletion and insertion mutations induced by the topoisomerase II inhibitor teniposide in CHO cells and comparison with sites of drug-stimulated DNA cleavage in vitro | Q45092712 | ||
| MDR1 (P-glycoprotein) gene expression--implications for resistance modifier trials | Q45233164 | ||
| Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer | Q45673258 | ||
| Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study | Q46147855 | ||
| A population model for the leukopenic effect of etoposide* | Q46780213 | ||
| Improvement of long-term survival in extensive small-cell lung cancer | Q47348667 | ||
| Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer | Q50538187 | ||
| The effect of the chemotherapeutic drug VP-16 on poly(ADP-ribosylation) in apoptotic HeLa cells. | Q52515744 | ||
| Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16). | Q53470150 | ||
| High-dose etoposide in treatment of metastatic breast cancer. | Q53850364 | ||
| Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. | Q54180477 | ||
| High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. | Q54180890 | ||
| P433 | issue | 3 | |
| P921 | main subject | etoposide | Q418817 |
| P304 | page(s) | 179-221 | |
| P577 | publication date | 1996-05-01 | |
| P1433 | published in | Cancer Treatment Reviews | Q1955762 |
| P1476 | title | The clinical pharmacology of etoposide: an update | |
| P478 | volume | 22 |
| Q36673831 | A Phase I/II Study of a 72-h Continuous Infusion of Etoposide in Advanced Soft Tissue Sarcoma. |
| Q36614847 | A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours |
| Q77713979 | A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer |
| Q33370478 | Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile |
| Q78223936 | Comparative in vitro and in vivo assessment of genotoxic effects of etoposide and chlorothalonil by the comet assay |
| Q42541938 | Discovery of podophyllotoxins |
| Q33688244 | Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma. |
| Q82341156 | Effects of camptothecin, etoposide and Ca2+ on caspase-3 activity and myofibrillar disruption of chicken during postmortem ageing |
| Q44117859 | Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines. |
| Q38713622 | Inhibition of T24 and RT4 Human Bladder Cancer Cell Lines by Heterocyclic Molecules |
| Q40210754 | Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. |
| Q37334609 | Metnase mediates chromosome decatenation in acute leukemia cells |
| Q40799677 | Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide |
| Q77761715 | Practical treatment guide for dose individualisation in cancer chemotherapy |
| Q61797728 | Protective role of N-acetylcysteine (NAC) on human sperm exposed to etoposide |
| Q27005726 | Recent progress on C-4-modified podophyllotoxin analogs as potent antitumor agents |
| Q33371779 | Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck |
| Q35105580 | Synthesis of novel spin-labeled podophyllotoxin derivatives as potential antineoplastic agents: Part XXV |
| Q36493495 | The role of chemotherapy in the treatment of malignant astrocytomas |
| Q44423318 | The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration |
| Q89301143 | Transdermal Delivery of Etoposide Phosphate I: In Vitro and In Vivo Evaluation |
Search more.